Highbridge Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Highbridge Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,534	Closed	-$247K	–	1689
2016 Q3	$247K	Buy	+6,534	New	+$144K	﹤0.01%	1084
2015 Q4	–	Sell	-51,757	Closed	-$918K	–	1907
2015 Q3	$918K	Sell	51,757 -18,350	-26%	-$332K	0.01%	805
2015 Q2	$1.24M	Buy	+70,107	New	+$1.29M	0.02%	663
2014 Q4	–	Sell	-20,360	Closed	-$421K	–	1508
2014 Q3	$421K	Buy	+20,360	New	+$401K	0.01%	896

Other funds holding AERI

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's AERI Position: Q4 2016 in Review

Highbridge Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2016, closing a stake of 6,534 shares — an estimated $247K sold.

Highbridge Capital Management first reported a position in AERI in Q3 2014 and held it in 4 quarters. The position peaked at $1.24M in Q2 2015. 151 funds tracked by Wall St. Rank hold AERI as of Q4 2016.

Highbridge Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 6,534 Aerie Pharmaceuticals shares in Q4 2016, an estimated $247K.
Highbridge Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Highbridge Capital Management's Aerie Pharmaceuticals position peaked at $1.24M in Q2 2015.
151 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.